Compare AbCellera Biologics Inc (ABCL) vs Aon PLC (AON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Aon PLC — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Aon PLC trades at $359.18 (market cap $76.85B). The key difference: Aon PLC is far larger — about 32.7× AbCellera Biologics Inc's market cap, and Aon PLC pays a 0.91% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AON | |
|---|---|---|
Market Cap | $2.35B | $76.85B |
Sector | Health | Financials |
52-Week High | $8.12 | $375.27 |
52-Week Low | $2.78 | $308.22 |
Enterprise Value | $1.99B | $90.91B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AON trades at $359.82, up 0.66% with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 22.54% net income margin and 46.82% ROE, supported by revenue growth to $17.18B in 2025. Analyst consensus is a Buy with a $385.50 price target, and the company continues to innovate with initiatives like the Aon DPX platform launch in 2026.
Outlook remains positive driven by AI integration and strategic growth, though risks include debt levels and market volatility. The stock offers upside potential near consensus targets, but investors should monitor execution of the 3x3 plan and competitive pressures in the insurance brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →
